Abstract:The prognosis of glioblastomas is still extremely poor and the discovery of novel molecular therapeutic targets can be important to optimize treatment strategies. Gene expression analyses comparing normal and neoplastic tissues have been used to identify genes associated with tumorigenesis and potential therapeutic targets. We have used this approach to identify differentially expressed genes between primary glioblastomas and non-neoplastic brain tissues. We selected 20 overexpressed genes related to cell cycle, cellular movement and growth, proliferation and cell-to-cell signaling and analyzed their expression levels by real time quantitative PCR in cDNA obtained from microdissected fresh tumor tissue from 20 patients with primary glioblastomas and from 10 samples of non-neoplastic white matter tissue. The gene expression levels were significantly higher in glioblastomas than in non-neoplastic white matter in 18 out of 20 genes analyzed: P < 0.00001 for CDKN2C, CKS2, EEF1A1, EMP3, PDPN, BNIP2, CA12, CD34, CDC42EP4, PPIE, SNAI2, GDF15 and MMP23b; and NFIA (P: 0.0001), GPS1 (P: 0.0003), LAMA1 (P: 0.002), STIM1 (P: 0.006), and TASP1 (P: 0.01). Five of these genes are located in contiguous loci at 1p31–36 and 2 at 17q24–25 and 8 of them encode surface membrane proteins. PDPN and CD34 protein expression were evaluated by immunohistochemistry and they showed concordance with the PCR results. The present results indicate the presence of 18 overexpressed genes in human primary glioblastomas that may play a significant role in the pathogenesis of these tumors and that deserve further functional investigation as attractive candidates for new therapeutic targets.

What problem does this paper attempt to address?

This paper aims to solve the key problems in the treatment of glioblastoma. Specifically, the goal of the research is to identify differentially expressed genes that may be involved in the tumorigenesis and development process by comparing the gene expression profiles of primary glioblastoma and non - tumor brain tissues, thereby discovering new molecular treatment targets. This helps to optimize treatment strategies and improve the current extremely poor prognosis of glioblastoma. ### Research Background - **Glioblastoma**: It is one of the most common adult brain tumors, highly malignant, and the median survival time is usually no more than 12 months. Although in recent years, there has been an in - depth understanding of the biological characteristics of this tumor, no breakthrough has been made in more effective treatment methods. - **Gene expression analysis**: By comparing the gene expression patterns of normal and tumor tissues, molecular changes that lead to tumorigenesis and progression can be revealed, and then new molecular treatment targets can be identified. ### Research Methods 1. **Sample collection**: Fresh surgical specimens were obtained from 20 patients with primary glioblastoma and 10 non - tumor brain tissues (epilepsy surgery samples in temporal lobectomy). 2. **RNA extraction and cDNA synthesis**: Total RNA was extracted using TRIzol LS Reagent, and single - stranded cDNA was synthesized by reverse transcription. 3. **Microarray analysis**: The oligonucleotide microarray (CodeLink Bioarrays - Human Uniset I) was used to compare the expression patterns of 10,000 genes in glioblastoma and non - tumor brain tissues. 4. **Real - time quantitative PCR verification**: Twenty over - expressed genes related to cell cycle, cell movement and growth, proliferation, and intercellular signal transduction were selected and verified by real - time quantitative PCR (RQ - PCR) in 30 independent samples. 5. **Immunohistochemical analysis**: Immunohistochemical analysis was performed on the expressions of podoplanin and CD34 proteins to verify the PCR results. ### Main Findings - **Microarray analysis**: 562 at least 2 - fold over - expressed genes and 630 low - expressed genes were found. - **RQ - PCR verification**: Among the 20 over - expressed genes, the expressions of 18 genes in glioblastoma were significantly higher than those in non - tumor brain tissues (P < 0.00001 to P < 0.01), including CDKN2C, CKS2, EEF1A1, EMP3, PDPN, BNIP1, CA12, CD34, CDC42EP4, PPIE, SNAI2, GDF15, MMP23b, NFIA, GPS1, LAMA1, STIM1 and TASP1. - **Gene location**: Five of these genes are located in the 1p31 - 36 region, two genes are located in the 17q24 - 25 region, and eight genes encode surface membrane proteins. - **Immunohistochemistry**: The expressions of podoplanin and CD34 proteins were consistent with the PCR results, further confirming the over - expression of these genes in glioblastoma. ### Conclusion This study successfully identified 18 genes that were significantly over - expressed in primary glioblastoma through gene expression profile analysis. These genes may play an important role in the occurrence and development of glioblastoma and are worthy of further functional studies as potential new treatment targets.

Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Gene expression profiling and genetic markers in glioblastoma survival

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas

Gene Expression Patterns Associated with Survival in Glioblastoma

Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma

Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens

Investigation gene and microRNA expression in glioblastoma

BIOM-35. A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE

Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response

In Silico Analysis Identified Mirna-Based Therapeutic Agents Against Glioblastoma Multiforme

Isolation of Novel Differentially Expressed Genes Related to Human Glioma Using CDNA Microarray and Characterizations of Two Novel Full-length Genes